The FDA dashed Amag Pharmaceuticals' hopes for its anemia drug Feraheme. The agency rejected Amag's application for broader use of the treatment for iron deficiency, citing a lack of evidence of its safety. The drug is approved to treat anemia in patients with chronic kidney disease, but Amag wanted to market it to a much broader group of anemia patients. Release | Report